Cern Corporation Introduces Non-Drug Treatment for Yeast & Bacterial Vaginosis

Cern Corporation has developed a novel non-drug treatment which is effective for both yeast & bacterial vaginosis

Why is this important?

Yeast and or bacterial GYN infection is the #1 reason so many women see their physician. According to US census data combined with CDC rates of prevalence, there are as many as 30M women in the US, who may be recurrent with these indications, under physician care.

For many, a new or repeated prescription for systemic antifungals or antibiotics, may not be an effective or desired, approach, based on pathogen resistance, drug sensitivities or compatibility with other drugs they may be taking. Cern’s unique/patented approach leverages safe, low level, microbicidal light (non UV), which is paired with a proprietary photosensitizer/”Gel” and has been documented in lab studies, and now also in human study, to be safe and highly effective in addressing these indications.

The device/"Gel" treatment can be considered “selective” in that the mechanism of action impacts both yeast and bacterial pathogen, yet preserves key native bacteria such as Lactobacillus, which is an essential component of a healthy, balanced, vaginal microbiome. Cern’s approach solves a significant “Unmet Need” for millions of women as well as clinicians who seek effective treatment as well as reduction of complications associated with drug-based therapies when addressing these indications.

Cern’s approach will be a platform for telemedicine in that sensor data may be reviewed by patient and care provider, thus addressing a significant interest to support “remote” or rural populations. The Device/Treatment will be an FDA Class II prescriptive, designed for home use, as needed, when needed, based on recurrent, familiar symptoms. The Cern Device/Treatment will be FDA Class II, and is now in clinical study. The device is not FDA cleared for sale in the US, nor internationally at this time.

To learn more about Cern’s significant new treatment, or if you are interested in participating in their study here in Orange County, CA, please send a note to Info@CernDevice.com

SOURCE: Cern Corporation